- Home
- WATT vs PALI Comparison
WATT vs PALI Comparison
Compare WATT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- PALI
- Stock Information
- Founded
- WATT 2012
- PALI 1996
- Country
- WATT United States
- PALI United States
- Employees
- WATT N/A
- PALI N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WATT Technology
- PALI Health Care
- Exchange
- WATT Nasdaq
- PALI Nasdaq
- Market Cap
- WATT 3.9M
- PALI 3.5M
- IPO Year
- WATT 2014
- PALI N/A
- Fundamental
- Price
- WATT $0.30
- PALI $1.78
- Analyst Decision
- WATT Strong Buy
- PALI Strong Buy
- Analyst Count
- WATT 2
- PALI 2
- Target Price
- WATT $2.25
- PALI $23.00
- AVG Volume (30 Days)
- WATT 350.0K
- PALI 3.7M
- Earning Date
- WATT 11-12-2024
- PALI 11-12-2024
- Dividend Yield
- WATT N/A
- PALI N/A
- EPS Growth
- WATT N/A
- PALI N/A
- EPS
- WATT N/A
- PALI N/A
- Revenue
- WATT $431,184.00
- PALI N/A
- Revenue This Year
- WATT $95.75
- PALI N/A
- Revenue Next Year
- WATT $834.07
- PALI N/A
- P/E Ratio
- WATT N/A
- PALI N/A
- Revenue Growth
- WATT N/A
- PALI N/A
- 52 Week Low
- WATT $0.28
- PALI $1.38
- 52 Week High
- WATT $2.75
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- WATT 21.40
- PALI 41.27
- Support Level
- WATT $0.28
- PALI $1.72
- Resistance Level
- WATT $0.34
- PALI $2.20
- Average True Range (ATR)
- WATT 0.04
- PALI 0.38
- MACD
- WATT -0.00
- PALI 0.02
- Stochastic Oscillator
- WATT 7.55
- PALI 19.27
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.